637 related articles for article (PubMed ID: 29091516)
21. Bosutinib : a review of preclinical and clinical studies in chronic myelogenous leukemia.
Rusconi F; Piazza R; Vagge E; Gambacorti-Passerini C
Expert Opin Pharmacother; 2014 Apr; 15(5):701-10. PubMed ID: 24479382
[TBL] [Abstract][Full Text] [Related]
22. The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib.
Castagnetti F; Gugliotta G; Breccia M; Iurlo A; Levato L; Albano F; Vigneri P; Abruzzese E; Rossi G; Rupoli S; Cavazzini F; Martino B; Orlandi E; Pregno P; Annunziata M; Usala E; Tiribelli M; Sica S; Bonifacio M; Fava C; Gherlinzoni F; Bocchia M; Soverini S; Bochicchio MT; Cavo M; Giovanni M; Saglio G; Pane F; Baccarani M; Rosti G;
Am J Hematol; 2017 Aug; 92(8):797-805. PubMed ID: 28466557
[TBL] [Abstract][Full Text] [Related]
23. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs.
Réa D; Mauro MJ; Boquimpani C; Minami Y; Lomaia E; Voloshin S; Turkina A; Kim DW; Apperley JF; Abdo A; Fogliatto LM; Kim DDH; le Coutre P; Saussele S; Annunziata M; Hughes TP; Chaudhri N; Sasaki K; Chee L; García-Gutiérrez V; Cortes JE; Aimone P; Allepuz A; Quenet S; Bédoucha V; Hochhaus A
Blood; 2021 Nov; 138(21):2031-2041. PubMed ID: 34407542
[TBL] [Abstract][Full Text] [Related]
24. Comparison of Hepatotoxicity Associated With New BCR-ABL Tyrosine Kinase Inhibitors vs Imatinib Among Patients With Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis.
Wang Z; Wang X; Wang Z; Feng Y; Jia Y; Jiang L; Xia Y; Cao J; Liu Y
JAMA Netw Open; 2021 Jul; 4(7):e2120165. PubMed ID: 34292334
[TBL] [Abstract][Full Text] [Related]
25. Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia.
Gambacorti-Passerini C; Cortes JE; Lipton JH; Dmoszynska A; Wong RS; Rossiev V; Pavlov D; Gogat Marchant K; Duvillié L; Khattry N; Kantarjian HM; Brümmendorf TH
Am J Hematol; 2014 Oct; 89(10):947-53. PubMed ID: 24944159
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety following bosutinib dose reduction in patients with Philadelphia chromosome‒positive leukemias.
Kota V; Brümmendorf TH; Gambacorti-Passerini C; Lipton JH; Kim DW; An F; Leip E; Crescenzo RJ; Ferdinand R; Cortes JE
Leuk Res; 2021 Dec; 111():106690. PubMed ID: 34673442
[TBL] [Abstract][Full Text] [Related]
27. Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib.
Cortes JE; Khoury HJ; Kantarjian HM; Lipton JH; Kim DW; Schafhausen P; Matczak E; Leip E; Noonan K; Brümmendorf TH; Gambacorti-Passerini C
Am J Hematol; 2016 Dec; 91(12):1206-1214. PubMed ID: 27531525
[TBL] [Abstract][Full Text] [Related]
28. Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia?
Kong JH; Winton EF; Heffner LT; Chen Z; Langston AA; Hill B; Arellano M; El-Rassi F; Kim A; Jillella A; Kota VK; Bodó I; Khoury HJ
Cancer; 2017 Jul; 123(13):2482-2488. PubMed ID: 28241101
[TBL] [Abstract][Full Text] [Related]
29. Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial.
Brümmendorf TH; Cortes JE; Milojkovic D; Gambacorti-Passerini C; Clark RE; le Coutre P; Garcia-Gutierrez V; Chuah C; Kota V; Lipton JH; Rousselot P; Mauro MJ; Hochhaus A; Hurtado Monroy R; Leip E; Purcell S; Yver A; Viqueira A; Deininger MW;
Leukemia; 2022 Jul; 36(7):1825-1833. PubMed ID: 35643868
[TBL] [Abstract][Full Text] [Related]
30. Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia.
Kwak JY; Kim SH; Oh SJ; Zang DY; Kim H; Kim JA; Do YR; Kim HJ; Park JS; Choi CW; Lee WS; Mun YC; Kong JH; Chung JS; Shin HJ; Kim DY; Park J; Jung CW; Bunworasate U; Comia NS; Jootar S; Reksodiputro AH; Caguioa PB; Lee SE; Kim DW
Clin Cancer Res; 2017 Dec; 23(23):7180-7188. PubMed ID: 28939746
[No Abstract] [Full Text] [Related]
31. Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia.
Cortes JE; Gambacorti-Passerini C; Deininger MW; Mauro MJ; Chuah C; Kim DW; Milojkovic D; le Coutre P; Garcia-Gutierrez V; Crescenzo R; Mamolo C; Reisman A; Hochhaus A; Brümmendorf TH;
J Cancer Res Clin Oncol; 2019 Jun; 145(6):1589-1599. PubMed ID: 30989330
[TBL] [Abstract][Full Text] [Related]
32. Comparative Effectiveness of Newer Tyrosine Kinase Inhibitors Versus Imatinib in the First-Line Treatment of Chronic-Phase Chronic Myeloid Leukemia Across Risk Groups: A Systematic Review and Meta-Analysis of Eight Randomized Trials.
Yun S; Vincelette ND; Segar JM; Dong Y; Shen Y; Kim DW; Abraham I
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e85-94. PubMed ID: 27101984
[TBL] [Abstract][Full Text] [Related]
33. Bosutinib: a novel second-generation tyrosine kinase inhibitor.
Isfort S; Keller-v Amsberg G; Schafhausen P; Koschmieder S; Brümmendorf TH
Recent Results Cancer Res; 2014; 201():81-97. PubMed ID: 24756786
[TBL] [Abstract][Full Text] [Related]
34. Prognostic Implication of BCR-ABL Fusion Transcript Variants in Chronic Myeloid Leukemia (CML) Treated with Imatinib. A First of Its Kind Study on CML Patients of Kashmir.
Azad NA; Shah ZA; Pandith AA; Khan MS; Rasool R; Rasool J; Aziz SA
Asian Pac J Cancer Prev; 2018 Jun; 19(6):1479-1485. PubMed ID: 29936718
[TBL] [Abstract][Full Text] [Related]
35. Long-term patient-reported outcomes from an open-label safety and efficacy study of bosutinib in Philadelphia chromosome-positive chronic myeloid leukemia patients resistant or intolerant to prior therapy.
Kantarjian HM; Mamolo CM; Gambacorti-Passerini C; Cortes JE; Brümmendorf TH; Su Y; Reisman AL; Shapiro M; Lipton JH
Cancer; 2018 Feb; 124(3):587-595. PubMed ID: 29072772
[TBL] [Abstract][Full Text] [Related]
36. Bosutinib: Valuable therapeutic option for the Bulgarian market.
Uzunova KH; Filipova EP; Vekov TY
J Cancer Res Ther; 2018; 14(5):909-915. PubMed ID: 30197324
[TBL] [Abstract][Full Text] [Related]
37. Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
Irvine E; Williams C
Pharmacotherapy; 2013 Aug; 33(8):868-81. PubMed ID: 23553655
[TBL] [Abstract][Full Text] [Related]
38. Bosutinib treatment for Philadelphia chromosome-positive leukemias.
Bethelmie-Bryan B; Lord K; Holloway S; Khoury HJ
Future Oncol; 2014 Feb; 10(2):179-85. PubMed ID: 24490604
[TBL] [Abstract][Full Text] [Related]
39. Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients.
García-Gutiérrez V; Milojkovic D; Hernandez-Boluda JC; Claudiani S; Martin Mateos ML; Casado-Montero LF; González G; Jimenez-Velasco A; Boque C; Martinez-Trillos A; Vázquez IM; Payer ÁR; Senín A; Amustio Díez E; García AB; Carrascosa GB; Ortí G; Ruiz BC; Fernández MÁ; Del Carmen García Garay M; Giraldo P; Guinea JM; De Las Heras Rodríguez N; Hernán N; Pérez AI; Piris-Villaespesa M; Lorenzo JLL; Martí-Tutusaus JMM; Vallansot RO; Ortega Rivas F; Puerta JM; Ramirez MJ; Romero E; Romo A; Rosell A; Saavedra SS; Sebrango A; Tallon J; Valencia S; Portero A; Steegmann JL;
Ann Hematol; 2019 Feb; 98(2):321-330. PubMed ID: 30446802
[TBL] [Abstract][Full Text] [Related]
40. Bosutinib for the treatment of chronic myeloid leukemia in chronic phase.
Quintás-Cardama A; Kantarjian H; Cortes J
Drugs Today (Barc); 2012 Mar; 48(3):177-88. PubMed ID: 22462037
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
